2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
Matthew Matasar, MD, chief, Division of Blood Disorders, hematologist, oncologist, professor of medicine, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, discusses the primary analysis of the phase 1 ELM-1 study (NCT02290951) assessing the efficacy and safety of odronextamab (Ordspono) monotherapy in patients with diffuse large B-cell lymphoma following treatment with CAR T-cell therapy. Matasar and colleagues shared this data during the 2024 ASH Annual Meeting.
Related Content: